![Afatinib Therapy: Practical Management of Adverse Events With an Oral Agent for Non-Small Cell Lung Cancer Treatment | ONS Afatinib Therapy: Practical Management of Adverse Events With an Oral Agent for Non-Small Cell Lung Cancer Treatment | ONS](https://www.ons.org/sites/default/files/journal-images/EdwardsOctoberCJONTable2.png)
Afatinib Therapy: Practical Management of Adverse Events With an Oral Agent for Non-Small Cell Lung Cancer Treatment | ONS
![Drug-Drug Interactions, Safety, and Pharmacokinetics of EGFR Tyrosine Kinase Inhibitors for the Treatment of Non-Small Cell Lung Cancer. - Abstract - Europe PMC Drug-Drug Interactions, Safety, and Pharmacokinetics of EGFR Tyrosine Kinase Inhibitors for the Treatment of Non-Small Cell Lung Cancer. - Abstract - Europe PMC](https://europepmc.org/articles/PMC6302998/bin/jadp-09-189-g01.jpg)
Drug-Drug Interactions, Safety, and Pharmacokinetics of EGFR Tyrosine Kinase Inhibitors for the Treatment of Non-Small Cell Lung Cancer. - Abstract - Europe PMC
POZIOTINIB FOR THE TREATMENT OF PATIENTS WITH PREVIOUSLY TREATED LOCALLY ADVANCED OR METASTATIC NON-SMALL CELL LUNG CANCER HARBO
![Selectivity profile of afatinib for EGFR-mutated non-small-cell lung cancer - Molecular BioSystems (RSC Publishing) DOI:10.1039/C6MB00038J Selectivity profile of afatinib for EGFR-mutated non-small-cell lung cancer - Molecular BioSystems (RSC Publishing) DOI:10.1039/C6MB00038J](https://pubs.rsc.org/image/article/2016/MB/c6mb00038j/c6mb00038j-f1_hi-res.gif)
Selectivity profile of afatinib for EGFR-mutated non-small-cell lung cancer - Molecular BioSystems (RSC Publishing) DOI:10.1039/C6MB00038J
These highlights do not include all the information needed to use GILOTRIF safely and effectively. See full prescribing informat
![Nilotinib Alters the Efflux Transporter-Mediated Pharmacokinetics of Afatinib in Mice - ScienceDirect Nilotinib Alters the Efflux Transporter-Mediated Pharmacokinetics of Afatinib in Mice - ScienceDirect](https://ars.els-cdn.com/content/image/1-s2.0-S0022354919303612-gr1.jpg)
Nilotinib Alters the Efflux Transporter-Mediated Pharmacokinetics of Afatinib in Mice - ScienceDirect
![Afatinib beyond progression in patients with non-small-cell lung cancer following chemotherapy, erlotinib/gefitinib and afatinib: phase III randomized LUX-Lung 5 trial - ScienceDirect Afatinib beyond progression in patients with non-small-cell lung cancer following chemotherapy, erlotinib/gefitinib and afatinib: phase III randomized LUX-Lung 5 trial - ScienceDirect](https://ars.els-cdn.com/content/image/1-s2.0-S0923753419355942-gr1.jpg)
Afatinib beyond progression in patients with non-small-cell lung cancer following chemotherapy, erlotinib/gefitinib and afatinib: phase III randomized LUX-Lung 5 trial - ScienceDirect
![Nilotinib Alters the Efflux Transporter-Mediated Pharmacokinetics of Afatinib in Mice - ScienceDirect Nilotinib Alters the Efflux Transporter-Mediated Pharmacokinetics of Afatinib in Mice - ScienceDirect](https://ars.els-cdn.com/content/image/1-s2.0-S0022354919303612-gr3.jpg)